Zentalis Pharmaceuticals (ZNTL) Asset Writedowns and Impairment (2023 - 2025)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Asset Writedowns and Impairment of $3.0 million for Q4 2025, up 159.03% quarter-over-quarter from $1.2 million in Q1 2025.
Powered by 
Analysis
Zentalis Pharmaceuticals (ZNTL) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends
Zentalis Pharmaceuticals' Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $3.0 million for Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.0 million (up 159.03% YoY), while the FY2025 annual figure was $4.1 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at $3.0 million, up from $1.2 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $5.0 million in Q1 2023, with the low at -$8.8 million in Q4 2021.
- The 3-year median for Asset Writedowns and Impairment is $2.1 million (2025), against an average of $72250.0.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Zentalis Pharmaceuticals | 282.81 Mn | 282.81 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 2.98 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Mar 31, 2023 | 4.95 Mn |